Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACAV: Efficacy and Safety of Alirocumab to Prevent Early Cardiac Allograft Vasculopathy
2024-514023-42-00Phase 4Completed
- Sponsor
- Institute for Clinical and Experimental Medicine
- Start
- Dec 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised trial in coronary vasculopathy comparing Alirocumab with Placebo (2 arms). Primary endpoint: Mean level of lipids and lipoproteins over treatment visits. Started Dec 2024; status: completed.
02
Drugs
alirocumab
03
Conditions
coronary vasculopathy
Beyond the preview
Go deeper on 2024-514023-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514023-42-00.